Coumetarol (Dicumoxane)
(Synonyms: 库美香豆素; Dicumoxane; Ph 137) 目录号 : GC33781
Coumetarol (Dicumoxane) (Dicumoxane) 是一种维生素 K 拮抗剂。
Cas No.:4366-18-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Coumetarol (Dicumoxane) is a vitamin K antagonist.
Coumetarol (Dicumoxane), an oral anticoagulant, is active in both models. The vitamin K antagonist Coumetarol is effective in both models after oral treatment but inhibits the thrombus formation more strongly in the arterio-venous shunt model. Treatment with the vitamin K antagonist Coumetarol in a dose of 25 mg/kg p.o. twice daily for 2 days results in a significant reduction in thrombus weight by 50% in the venous stasis model and by 75% in the arterio-venous shunt model. In both experiments the coagulation time as measured by the Thrombotest is prolonged to the same extent[1].
[1]. Vogel GM, et al. Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans. Thromb Res. 1989 Jun 1;54(5):399-410.
| Cas No. | 4366-18-1 | SDF | |
| 别名 | 库美香豆素; Dicumoxane; Ph 137 | ||
| Canonical SMILES | COCC(C1=C(O)C2=CC=CC=C2OC1=O)C3=C(O)C4=CC=CC=C4OC3=O | ||
| 分子式 | C21H16O7 | 分子量 | 380.35 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6292 mL | 13.1458 mL | 26.2916 mL |
| 5 mM | 0.5258 mL | 2.6292 mL | 5.2583 mL |
| 10 mM | 0.2629 mL | 1.3146 mL | 2.6292 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans
Thromb Res 1989 Jun 1;54(5):399-410.PMID:2549654DOI:10.1016/0049-3848(89)90210-7
Two experimental thrombosis models in rats have been compared with regard to the composition of the formed thrombi and the effects of various treatments on thrombus formation. In the first model thrombosis is induced in the vena cava by a combination of venous stasis and hypercoagulability; these thrombi consist merely of red cells and fibrin with only a few platelets. In the second model thrombosis is induced in an arterio-venous shunt in which the formed thrombi consist of red cells, fibrin and a large amount of platelet aggregates adhering to the foreign material. Antiplatelet serum and acetylsalicylic acid, which reduce blood platelet activity, inhibited thrombus formation only in the arteriovenous shunt model. Dicumoxane, an oral anticoagulant, was active in both models. The glycosaminoglycans heparin, Org 10172, Fragmin and the pentasaccharide, representing the AT-III binding sequence of heparin, were active in both models. However, there were qualitative and quantitative differences between the effects of the glycosaminoglycans suggesting differences in their modes of action.